1. Signaling Pathways
  2. Cell Cycle/DNA Damage
  3. CDK

CDK

Cyclin dependent kinase

CDKs (Cyclin-dependent kinases) are serine-threonine kinases first discovered for their role in regulating the cell cycle. They are also involved in regulating transcription, mRNA processing, and the differentiation of nerve cells. CDKs are relatively small proteins, with molecular weights ranging from 34 to 40 kDa, and contain little more than the kinase domain. In fact, yeast cells can proliferate normally when their CDK gene has been replaced with the homologous human gene. By definition, a CDK binds a regulatory protein called a cyclin. Without cyclin, CDK has little kinase activity; only the cyclin-CDK complex is an active kinase.

There are around 20 Cyclin-dependent kinases (CDK1-20) known till date. CDK1, 4 and 5 are involved in cell cycle, and CDK 7, 8, 9 and 11 are associated with transcription.

CDK levels remain relatively constant throughout the cell cycle and most regulation is post-translational. Most knowledge of CDK structure and function is based on CDKs of S. pombe (Cdc2), S. cerevisia (CDC28), and vertebrates (CDC2 and CDK2). The four major mechanisms of CDK regulation are cyclin binding, CAK phosphorylation, regulatory inhibitory phosphorylation, and binding of CDK inhibitory subunits (CKIs).

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-47733
    CDK1/2/4-IN-2
    Inhibitor
    WAY-643018 (Compound 2), an indazolecarboxamide derivative, is a CDK1, CDK2, and CDK4 inhibitor. CDK1/2/4-IN-2 has the potential for cancer research.
    CDK1/2/4-IN-2
  • HY-RS18382
    Cdk10 Mouse Pre-designed siRNA Set A

    Cdk10 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Cdk10 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

    Components

    Cdk10 siRNA-1: 5 nmol (HPLC)

    Cdk10 siRNA-2: 5 nmol (HPLC)

    Cdk10 siRNA-3: 5 nmol (HPLC)

    siRNA Negative Control: 5 nmol (HPLC)

    FAM-labeled siRNA Negative Control: 5 nmol (HPLC)

    GAPDH siRNA Positive Control: 5 nmol (HPLC)

    Cdk10 Mouse Pre-designed siRNA Set A
  • HY-159937
    PKMYT1-IN-7
    Inhibitor
    PKMYT1-IN-7 (compound 7) is an orally active PKMYT1 inhibitor with IC50 values of 1.6 nM and 0.06 μM against of PKMYT1 and pCDK1, respectively. PKMYT1-IN-7 suppresses the phosphorylation of CDK1 at T14 and Y15. PKMYT1-IN-7 shows anticancer activity both < and <.
    PKMYT1-IN-7
  • HY-N5072R
    Desmethylglycitein (Standard)
    Inhibitor
    Desmethylglycitein (4',6,7-Trihydroxyisoflavone), a metabolite of daidzein, sourced from Glycine max with antioxidant, and anti-cancer activities. Desmethylglycitein binds directly to CDK1 and CDK2 in vivo, resulting in the suppresses CDK1 and CDK2 activity. Desmethylglycitein is a direct inhibitor of protein kinase C (PKC)α, against solar UV (sUV)-induced matrix matrix metalloproteinase 1 (MMP1). Desmethylglycitein binds to PI3K in an ATP competitive manner in the cytosol, where it inhibits the activity of PI3K and downstream signaling cascades, leading to the suppression of adipogenesis in 3T3-L1 preadipocytes.
    Desmethylglycitein (Standard)
  • HY-118447
    RO0505124
    RO0505124 is a selective CDK4 inhibitor with an IC50 of 20 nM. RO0505124 reversibly binds the ATP pocket of the kinase. RO0505124 induces G1 phase arrest in cancer cells via reduced retinoblastoma protein (Rb) phosphorylation, blocking S phase progression. RO0505124 exhibits anti-proliferative activity against various cancer cells. RO0505124 delays mitosis, induces aberrant mitosis with lagging chromosomes, driving mitotic slippage and formation of multinucleated or micronucleated cells. RO0505124 inhibits G2/M phase accumulation of survivin and borealin. RO0505124 can be used for the research of cancer.
    RO0505124
  • HY-15777BR
    Ribociclib succinate (Standard)
    Inhibitor
    Ribociclib succinate (Standard) is the analytical standard of Ribociclib succinate. This product is intended for research and analytical applications. Ribociclib succinate (LEE011 succinate) is a highly specific CDK4/6 inhibitor with IC50 values of 10 nM and 39 nM, respectively, and is over 1,000-fold less potent against the cyclin B/CDK1 complex.
    Ribociclib succinate (Standard)
  • HY-147131
    CDK9-IN-30
    Inhibitor 98.0%
    CDK9-IN-30 is a CDK9 inhibitor that inhibits HIV-1 viral replication.
    CDK9-IN-30
  • HY-100950R
    ABC1183 (Standard)
    Inhibitor
    ABC1183 (Standard) is the analytical standard of ABC1183 (HY-100950). This product is intended for research and analytical applications. ABC1183 is an orally active selective dual GSK3 and CDK9 inhibitor. ABC1183 inhibits GSK3β, GSK3α and CDK9/cyclin T1 with the IC50 values of 657 nM, 327 nM and 321 nM, respectively. ABC1183 has anti-inflammatory and anti-tumor activities.
    ABC1183 (Standard)
  • HY-169683
    CDK2-IN-39
    Inhibitor
    CDK2-IN-39 (compound 4) is a CDK2 inhibitor.
    CDK2-IN-39
  • HY-103492R
    CDK8-IN-1 (Standard)
    Inhibitor
    CDK8-IN-1 (Standard) is the analytical standard of CDK8-IN-1 (HY-103492). This product is intended for research and analytical applications. CDK8-IN-1 is a potent and selective CDK8 inhibitor with an IC50 of 3 nM.
    CDK8-IN-1 (Standard)
  • HY-177373
    P21 saRNA
    Activator
    P21 saRNA is a small activating RNA (saRNA) targeting the p21 genes. P21 saRNA induce expression of the p21 genes, and targets the p21 promoters at ?322 relative to gene's transcription start site.
    P21 saRNA
  • HY-128669R
    Abemaciclib metabolite M2 (Standard)
    Inhibitor
    Abemaciclib metabolite M2 (Standard) is the analytical standard of Abemaciclib metabolite M2. This product is intended for research and analytical applications. Abemaciclib metabolite M2 (LSN2839567) is a metabolite of Abemaciclib, acts as a potent CDK4 and CDK6 inhibitor, with IC50s of 1.2 and 1.3 nM, respectively. Anti-cancer activity[1][2].
    Abemaciclib metabolite M2 (Standard)
  • HY-160185
    CDK2-IN-21
    Inhibitor
    CDK2-IN-21 (example 30) is a potent cyclin-dependent kinase 2 (CDK2) inhibitor with an IC50 of 0.24 µM. CDK2-IN-21 can be used for cancer research.
    CDK2-IN-21
  • HY-10424R
    Milciclib (Standard)
    Inhibitor
    Milciclib (Standard) is the analytical standard of Milciclib. This product is intended for research and analytical applications. Milciclib (PHA-848125) is a potent, ATP-competitive and dual inhibitor of CDK and Tropomyosin receptor kinase (TRK), with IC50s of 45, 150, 160, 363, 398 nM and 53 nM for cyclin A/CDK2, cyclin H/CDK7, cyclin D1/CDK4, cyclin E/CDK2, cyclin B/CDK1 and TRKA, respectively.
    Milciclib (Standard)
  • HY-10580R
    GSK 3 Inhibitor IX (Standard)
    Inhibitor
    GSK 3 Inhibitor IX (Standard) is the analytical standard of GSK 3 Inhibitor IX (HY-10580). This product is intended for research and analytical applications. GSK 3 Inhibitor IX (6-Bromoindirubin-3'-oxime; BIO) is a potent, selective, reversible and ATP-competitive inhibitor of GSK-3α/β and CDK1-cyclinB complex with IC50s of 5 nM/320 nM/80 nM for (GSK-3α/β)/CDK1/CDK5, respectively.
    GSK 3 Inhibitor IX (Standard)
  • HY-121174
    Alaternin
    Inhibitor
    Alaternin (Catharticin) is an anthraquinone compound with antioxidant and hepatoprotective activities. Alaternin has an inhibitory activity against hydroxyl radicals generated in a cell-free chemical system (FeSO4/H2O2) with an IC50 value of 3.05 μM. Alaternin exhibits hepatoprotective activity against Tacrine (HY-111338)-induced toxicity in human hepatic HepG2 cells with an EC50 value of 4.02 μM.
    Alaternin
  • HY-103646R
    CK7 (Standard)
    Inhibitor
    CK7 (Standard) is the analytical standard of CK7 (HY-103646). This product is intended for research and analytical applications. CK7, a Cdk2/9 inhibitor, can be used for the synthesis of Nek1 inhibitor BSc5231 and BSc5367.
    CK7 (Standard)
  • HY-111260
    R547 mesylate
    Inhibitor
    R547 mesylate is a potent, selective and orally active ATP-competitive CDK inhibitor, with Kis of 2 nM, 3 nM and 1 nM for CDK1/cyclin B, CDK2/cyclin E and CDK4/cyclin D1, respectively.
    R547 mesylate
  • HY-105310
    ZK 304709
    Inhibitor
    ZK 304709 is a multi-target CDK inhibitor.
    ZK 304709
  • HY-101467R
    Trilaciclib (Standard)
    Inhibitor
    Trilaciclib (Standard) is the analytical standard of Trilaciclib (HY-101467). This product is intended for research and analytical applications. Trilaciclib (G1T28) is an orally active CDK4/6 inhibitor with IC50 values of 1 nM and 4 nM for CDK4 and CDK6, respectively. . Trilaciclib can effectively inhibit tumor cell proliferation and reduce the hematological toxicity caused by chemotherapy. Trilaciclib attenuates apoptosis and myelosuppression induced by 5FU (HY-90006) chemotherapy.
    Trilaciclib (Standard)
Cat. No. Product Name / Synonyms Species Source
Cat. No. Product Name / Synonyms Application Reactivity

Your Search Returned No Results.

Sorry. There is currently no product that acts on isoform together.

Please try each isoform separately.